- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01172899
Bariatric Surgery in Children. (BASIC)
The BASIC Trial. Morbid Obesity in Children and Adolescents: a Prospective Randomised Trial of Conservative Treatment Versus Surgery
Rationale:
In the Western world overweight and obesity is an increasing problem both in adults and in children. In youth, it is associated with early death and a number of co-morbidities including metabolic and endocrine changes, increased inflammatory status, cardiovascular abnormalities, nonalcoholic fatty liver disease, and impaired quality of life.
The standard treatment for morbid obesity in children is by combined life style interventions. However, the medium and long term effects of dietetic interventions, behaviour therapy and medication is relatively poor. In adults bariatric surgery shows good results with up to 30% weight reduction in 3 years. The preliminary results in youth are similar, but surgery in this age group is relatively uncommon. In the Netherlands surgery in this age group is only allowed in clinical trials, until the benefits and risks have been established. (National Health Authorities)
Objective:
To determine if surgery gives a superior weight and body mass index (BMI) reduction than combined life style interventions in adolescents with morbid obesity and to assess its effect on obesity associated co-morbidity.
Study design:
Prospective randomised interventional study.
Study population:
Morbidly obese children, aged 14 - 16 years, with sex and age adjusted BMI >40 kg/m2 or >35 kg/m2 with co-morbidity.
Intervention:
Bariatric surgery by laparoscopic adjustable gastric band (LAGB) or combined life style interventions
Main study parameters/endpoints:
Primary endpoints: weight loss, loss of excess weight, loss of excess BMI. Secondary endpoints: Body composition, pubertal development, metabolic and endocrine changes, inflammatory status, cardiovascular abnormalities, non-alcoholic steatohepatitis, brain development, quality of life, and behaviour changes. The potential complications of surgery are monitored.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Limburg
-
Maastricht, Limburg, Países Bajos, 6202ZA
- Maastricht University Medical Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Aged 14 to 16
Age and sex adjusted BMI >40 kg/m2 or >35 kg/m2 with associated co-morbidity.
* Associated co-morbidity includes: glucose intolerance, type 2 diabetes, hypertension, pseudotumor cerebri, acanthosis nigricans, obstructive sleep apnoea syndrome, depression, arthropathies, non-alcoholic steatohepatitis and dyslipidemia.
- > 1 year multidisciplinary organized weight reducing attempts with less than 5% weight loss
- Demonstrate decisional capacity
Exclusion Criteria:
- Psychologically not suitable
- Pre-menarche or bone age <15 years in boys
- Obesity associated to other disorders such as hypothyroidism
- Syndromal disorders such as Prader-Willi syndrome
- Severe cardiorespiratory impairment (ASA class 3 or higher)
- Insufficiently fluid in the Dutch language
- Unwillingness to adhere to follow-up programmes
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: Grupo de control
|
Control group will receive standard therapy consisting of combined lifestyle interventions.
|
|
Experimental: Laparoscopic adjustable gastric band
|
Laparoscopic gastric band placement.
Combined lifestyle interventions will continue after surgery.
Control group will receive standard therapy consisting of combined lifestyle interventions.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Weight
Periodo de tiempo: 6 months
|
Weight loss, excess weight loss and loss of excess BMI.
|
6 months
|
|
Weight
Periodo de tiempo: 12 months
|
Weight loss, excess weight loss and loss of excess BMI.
|
12 months
|
|
Weight
Periodo de tiempo: 24 months
|
Weight loss, excess weight loss and loss of excess BMI.
|
24 months
|
|
Weight
Periodo de tiempo: 36 months
|
Weight loss, excess weight loss and loss of excess BMI.
|
36 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Body composition
Periodo de tiempo: 12 months
|
Next to anthropometric measurements, bone mineral content, bone density, lean bodymass and fat percentage will be assessed.
|
12 months
|
|
Pubertal development
Periodo de tiempo: 6 months
|
Follow-up of hormonal status and Tanner stages.
|
6 months
|
|
Metabolic and endocrine changes
Periodo de tiempo: 6 months
|
6 months
|
|
|
Inflammatory status
Periodo de tiempo: 6 months
|
Measurement of serum inflammatory markers.
|
6 months
|
|
Cardiovascular abnormalities
Periodo de tiempo: 6 months
|
6 months
|
|
|
Non-alcoholic fatty liver disease
Periodo de tiempo: 6 months
|
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured.
CCL-2 is used as a surrogate marker to assess liver disease.
|
6 months
|
|
Quality of life changes
Periodo de tiempo: 6 months
|
6 months
|
|
|
Behaviour changes
Periodo de tiempo: 6 months
|
Measuring impulsivity and positive reward dominance with a computer task.
|
6 months
|
|
Operative complications
Periodo de tiempo: up to 36 months
|
Early and late complications are being monitored
|
up to 36 months
|
|
Effects on sleep architecture
Periodo de tiempo: 6 months
|
6 months
|
|
|
Brain development
Periodo de tiempo: 6 months
|
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
|
6 months
|
|
Body composition
Periodo de tiempo: 24 months
|
Next to anthropometric measurements, bone mineral content, bone density, lean bodymass and fat percentage will be assessed.
|
24 months
|
|
Body composition
Periodo de tiempo: 36 months
|
Next to anthropometric measurements, bone mineral content, bone density, lean bodymass and fat percentage will be assessed.
|
36 months
|
|
Pubertal development
Periodo de tiempo: 12 months
|
Follow-up of hormonal status and Tanner stages.
|
12 months
|
|
Pubertal development
Periodo de tiempo: 24 months
|
Follow-up of hormonal status and Tanner stages.
|
24 months
|
|
Pubertal development
Periodo de tiempo: 36 months
|
Follow-up of hormonal status and Tanner stages.
|
36 months
|
|
Metabolic and endocrine changes
Periodo de tiempo: 12 months
|
12 months
|
|
|
Metabolic and endocrine changes
Periodo de tiempo: 24 months
|
24 months
|
|
|
Metabolic and endocrine changes
Periodo de tiempo: 36 months
|
36 months
|
|
|
Inflammatory status
Periodo de tiempo: 12 months
|
Measurement of serum inflammatory markers.
|
12 months
|
|
Inflammatory status
Periodo de tiempo: 24 months
|
Measurement of serum inflammatory markers.
|
24 months
|
|
Inflammatory status
Periodo de tiempo: 36 months
|
Measurement of serum inflammatory markers.
|
36 months
|
|
Cardiovascular abnormalities
Periodo de tiempo: 12 months
|
12 months
|
|
|
Cardiovascular abnormalities
Periodo de tiempo: 24 months
|
24 months
|
|
|
Cardiovascular abnormalities
Periodo de tiempo: 36 months
|
36 months
|
|
|
Non-alcoholic fatty liver disease
Periodo de tiempo: 12 months
|
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured.
CCL-2 is used as a surrogate marker to assess liver disease.
|
12 months
|
|
Non-alcoholic fatty liver disease
Periodo de tiempo: 24 months
|
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured.
CCL-2 is used as a surrogate marker to assess liver disease.
|
24 months
|
|
Non-alcoholic fatty liver disease
Periodo de tiempo: 36 months
|
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured.
CCL-2 is used as a surrogate marker to assess liver disease.
|
36 months
|
|
Quality of life changes
Periodo de tiempo: 12 months
|
12 months
|
|
|
Quality of life changes
Periodo de tiempo: 24 months
|
24 months
|
|
|
Quality of life changes
Periodo de tiempo: 36 months
|
36 months
|
|
|
Effects on sleep architecture
Periodo de tiempo: 12 months
|
12 months
|
|
|
Effects on sleep architecture
Periodo de tiempo: 24 months
|
24 months
|
|
|
Effects on sleep architecture
Periodo de tiempo: 36 months
|
36 months
|
|
|
Behaviour changes
Periodo de tiempo: 12 months
|
Measuring impulsivity and positive reward dominance with a computer task.
|
12 months
|
|
Behaviour changes
Periodo de tiempo: 24 months
|
Measuring impulsivity and positive reward dominance with a computer task.
|
24 months
|
|
Behaviour changes
Periodo de tiempo: 36 months
|
Measuring impulsivity and positive reward dominance with a computer task.
|
36 months
|
|
Brain development
Periodo de tiempo: 12 months
|
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
|
12 months
|
|
Brain development
Periodo de tiempo: 24 months
|
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
|
24 months
|
|
Brain development
Periodo de tiempo: 36 months
|
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
|
36 months
|
|
Physical activity
Periodo de tiempo: 6 months
|
Assessment of physical activity using a questionnaire and an accelerometer.
|
6 months
|
|
Physical activity
Periodo de tiempo: 12 months
|
Assessment of physical activity using a questionnaire and an accelerometer.
|
12 months
|
|
Physical activity
Periodo de tiempo: 24
|
Assessment of physical activity using a questionnaire and an accelerometer.
|
24
|
|
Physical activity
Periodo de tiempo: 36 months
|
Assessment of physical activity using a questionnaire and an accelerometer.
|
36 months
|
|
Behavior towards food
Periodo de tiempo: 6 months
|
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
|
6 months
|
|
Behavior towards food
Periodo de tiempo: 12 months
|
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
|
12 months
|
|
Behavior towards food
Periodo de tiempo: 24 months
|
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
|
24 months
|
|
Behavior towards food
Periodo de tiempo: 36 months
|
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
|
36 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: LWE van Heurn, Professor, Maastricht University Medical Center
- Investigador principal: Yvonne Roebroek, PhD Student, Maastricht University Medical Center
- Investigador principal: Givan F Paulus, PhD Student, Spaarne Gasthuis, Haarlem
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- NL26279.068.09
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .